GeneReach Biotechnology Corp.

As of June 30, 2026, GeneReach Biotechnology Corp. carries a market capitalization of 963.73M, placing it among publicly traded companies globally. Its enterprise value stands at 796.95M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, GeneReach Biotechnology Corp. has 56.86M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.07, and the price-to-book ratio stands at 1.68.

As of June 30, 2026, GeneReach Biotechnology Corp. trades at an EV/EBITDA multiple of 108.84 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 796.95M versus a market cap of 963.73M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, GeneReach Biotechnology Corp. maintains a current ratio of 2.41, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 37.88, indicating elevated leverage, while an interest coverage ratio of 1.40 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, GeneReach Biotechnology Corp. posted a negative return on equity (ROE) of -7.26, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.77, reflecting losses generated across the asset base. The company generates approximately 1.58M in revenue per employee across its workforce of 151.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.61 indicates how many times GeneReach Biotechnology Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, GeneReach Biotechnology Corp. recorded an income tax benefit of -3.97M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -49.82M and -43.09M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, GeneReach Biotechnology Corp.'s stock has declined approximately 9.81% over the past 52 weeks. The 50-day moving average sits at 16.99, while the 200-day moving average is 18.35.

Over the twelve months ended June 30, 2026, GeneReach Biotechnology Corp. generated 238.08M in revenue and converted that into -43.09M in net income, yielding earnings per share of -0.80. EBITDA reached 7.32M, while operating income came in at -59.36M.

As of June 30, 2026, GeneReach Biotechnology Corp. holds 395.82M in cash and equivalents against 220.26M in total debt, resulting in a net debt position of -8.32M. Total book value stands at 572.70M, with working capital of 280.30M providing operational flexibility.

GeneReach Biotechnology Corp. produced 13.63M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -15.66M in capital expenditures, free cash flow totaled -2.02M - equivalent to -0.04 per share.

Over the twelve months ended June 30, 2026, GeneReach Biotechnology Corp. posted a gross margin of 72.79, reflecting its pricing power and cost economics. The operating margin of -24.93 and net profit margin of -18.10 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 5.70, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to GeneReach Biotechnology Corp. shareholders.

GeneReach Biotechnology Corp.'s most recent stock split took place on July 28, 2023 with a 4:5 split ratio.

As of June 30, 2026, GeneReach Biotechnology Corp. has an Altman Z-Score of 2.20, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.